Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tokyo Aims To Speed Up Drug Approvals, Catch Up With U.S., Says Japanese Health Ministry Official

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan is in the process of aligning itself with global pharmaceutical standards, according to Shuichi Kishida, councilor for pharmaceutical safety at the Ministry of Health, Labor and Welfare

You may also be interested in...



Japan's MHLW Approves Request For Needed Drugs That Can Bypass Clinical Trials

TOKYO - Japan's Ministry of Health, Labor and Welfare is urging manufacturers to develop drugs for Japan that are still unapproved or unapproved for additional indications already approved in the West. Some drugs considered highly medically necessary may qualify for approval via a known-art application without conducting new clinical trials in Japan. The move is part of the ministry's ongoing efforts to reduce the country's much talked about drug lag

Japan's MHLW Approves Request For Needed Drugs That Can Bypass Clinical Trials

TOKYO - Japan's Ministry of Health, Labor and Welfare is urging manufacturers to develop drugs for Japan that are still unapproved or unapproved for additional indications already approved in the West. Some drugs considered highly medically necessary may qualify for approval via a known-art application without conducting new clinical trials in Japan. The move is part of the ministry's ongoing efforts to reduce the country's much talked about drug lag

Japanese, Chinese Regulators Step Up Communications To Increase Effectiveness, Speed Up Approval - DIA China Conference

BEIJING - Communication with regulators is essential for clinical development success and increasingly drug companies are engaging with multiple regulators simultaneously along parallel tracks; regulators are responding in some surprising ways that show they are willing to change, leaders from China and Japan told scientists and executives at the China Drug Information Association meeting in Beijing May 18

Related Content

UsernamePublicRestriction

Register

LL1134361

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel